Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
15.99
-0.31 (-1.90%)
Mar 2, 2026, 4:00 PM EST - Market closed
Pharming Group Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Pharming Group stock have an average target of 38, with a low estimate of 37 and a high estimate of 39. The average target predicts an increase of 137.65% from the current stock price of 15.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for Pharming Group stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +131.39% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +131.39% | Mar 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $39 | Buy | Maintains | $30 → $39 | +143.90% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +131.39% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +131.39% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
379.66M
from 297.20M
Increased by 27.75%
Revenue Next Year
415.30M
from 379.66M
Increased by 9.39%
EPS This Year
0.00
from -0.02
EPS Next Year
0.03
from 0.00
Increased by 1,170.00%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 394.9M | 477.0M | ||||
| Avg | 379.7M | 415.3M | ||||
| Low | 337.1M | 333.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 32.9% | 25.6% | ||||
| Avg | 27.7% | 9.4% | ||||
| Low | 13.4% | -12.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.04 | 0.07 | |||
| Avg | 0.00 | 0.03 | |||
| Low | -0.02 | -0.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 3,315.0% | |||
| Avg | - | 1,170.0% | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.